Wordt geladen...
Poxvirus vectors as HIV/AIDS vaccines in humans
The RV144 phase III clinical trial with the combination of the poxvirus vector ALVAC and the HIV gp120 protein has taught us that a vaccine against HIV/AIDS is possible but further improvements are still needed. Although the HIV protective effect of RV144 was modest (31.2%), these encouraging result...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Landes Bioscience
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3579898/ https://ncbi.nlm.nih.gov/pubmed/22906946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.20778 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|